Waters Corporation and BD’s Biosciences & Diagnostic Solutions Division Join Forces to Forge a New Leader in High-Volume Regulated Testing
MILFORD, MA and FRANKLIN LAKES, NJ – July 15, 2025 – In a significant development set to reshape the landscape of life sciences and diagnostics, Waters Corporation (NYSE: WAT) and Becton, Dickinson and Company (BD) (NYSE: BDX) today announced a definitive agreement to combine Waters’ industry-leading chromatography, mass spectrometry, and thermal analysis technologies with BD’s robust Biosciences and Diagnostic Solutions division. This strategic union will create a formidable new entity dedicated to advancing solutions for high-volume regulated testing markets.
The newly formed company will leverage the complementary strengths of both organizations, combining Waters’ renowned expertise in analytical instrumentation and informatics with BD’s deep-rooted presence and innovation in diagnostic and life science research solutions. The focus of this powerful collaboration will be on delivering integrated workflows and cutting-edge technologies that address the complex needs of regulated environments, including clinical diagnostics, pharmaceutical quality control, food safety, and environmental monitoring.
“This combination marks a pivotal moment for both Waters and BD, and more importantly, for the customers we serve,” said [Insert Name and Title of Waters CEO], President and CEO of Waters Corporation. “By bringing together our complementary capabilities, we are poised to accelerate innovation and provide unparalleled solutions that enhance accuracy, efficiency, and throughput in critical testing applications. Our shared commitment to scientific excellence and customer success makes this a natural and powerful partnership.”
The new entity aims to capitalize on the growing demand for sophisticated analytical tools capable of handling large volumes of samples with exceptional precision and reliability. This includes supporting the development and manufacturing of new therapies, ensuring the safety of our food and environment, and advancing the accuracy of medical diagnoses.
“BD’s Biosciences and Diagnostic Solutions division has a rich history of innovation and a strong track record of delivering trusted products to laboratories worldwide,” commented [Insert Name and Title of BD CEO], Chairman, President and CEO of BD. “Partnering with Waters, a recognized leader in analytical science, will significantly enhance our ability to serve the evolving needs of the diagnostic and life sciences sectors. Together, we will be uniquely positioned to empower our customers with comprehensive solutions that drive better patient outcomes and scientific discoveries.”
The combined company is expected to benefit from:
- Expanded Portfolio: A comprehensive suite of analytical technologies, including chromatography, mass spectrometry, spectroscopy, immunoassay, flow cytometry, and molecular diagnostics.
- Enhanced Innovation: Accelerated research and development efforts, fueled by a larger talent pool and combined intellectual property.
- Greater Market Reach: A significantly expanded global footprint and enhanced customer support capabilities across a broad spectrum of industries.
- Focus on Regulated Markets: Deep expertise and tailored solutions for the stringent requirements of highly regulated testing environments.
The transaction is subject to customary closing conditions, including regulatory approvals and the approval of Waters Corporation shareholders. Upon closing, the combined company will operate under a new name and brand identity to be announced at a later date. The leadership team and organizational structure of the new entity will also be finalized as part of the closing process.
This merger represents a significant step forward in providing the global scientific and healthcare communities with the advanced tools they need to tackle some of the world’s most pressing challenges. Both Waters and BD are committed to a smooth integration process and look forward to creating a truly impactful leader in the life sciences and diagnostics industries.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Regroupement de Waters et de la division Biosciences & Diagnostic Solutions de BD, Création d’un leader des sciences de la vie et du diagnostic axé sur les tests réglementés à haut volume’ at 2025-07-15 17:22. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.